SAN DIEGO , Aug. 12, 2022 /PRNewswire/ -- Cymbiotika, a leading nutritional supplement brand known for creating pure, clinically backed supplements, today announced a new partnership with Dr. Pejman Taghavi , who joins the Board of Advisors as a medical consultant.
Dr. Taghavi, Medical Director of Hollywood Healthcare and Diagnostic Imaging, joins Cymbiotikas Board of Advisors.
"In order for Cymbiotika to continue evolving and guide our customers towards optimal health, we require a wide range of advisors with expertise in healthcare and medicine. We are delighted to welcome Dr. Pejman Taghavi , who brings a wealth of knowledge in the field of Diagnostic and Interventional Abdominal and Musculoskeletal radiology. As Medical Director of Hollywood Healthcare and Diagnostic Imaging and a former clinical instructor at Ronald Reagan UCLA Medical Center, Dr. Taghavi is an experienced physician who has worked with professional athletes including the Los Angeles Lakers and Los Angeles Dodgers," said Shahab Elmi , CEO and founder of Cymbiotika.
"I'm very excited for this opportunity to partner with Cymbiotika," said Dr. Taghavi. "As a specialist in treating musculoskeletal injuries, I find that there is a lot of common ground between my approach to healing and Cymbiotika's approach to nutrition. Cymbiotika supplements are scientifically formulated with natural ingredients that are stringently tested for safety and purity. "
Cymbiotika is an innovative wellness brand based in San Diego . With the motto, "Your mind and body deserve the best", Cymbiotika is driven by the higher purpose of inspiring everyday people to achieve their optimal health. Founded in 2017, Cymbiotika uses the most advanced bioavailable absorption technology and sources only the highest quality plant-based nutrients to resolve specific nutritional deficiencies and support healthy aging, detoxification and longevity. Cymbiotika never uses synthetics, GMOs, fillers, chemicals, preservatives, additives or sugars in its products. For more information, visit https://cymbiotika.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cymbiotika-announces-partnership-with-medical-advisor-dr-pejman-taghavi-301605285.html
UNITY Biotechnology Inc (NASDAQ: UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). DME is a diabetic complication that affects the blood vessels in the back of your eye. At 18 weeks after a single UBX1325 injection, the mean change in BCVA of UBX1325-treated subjects was an increase of 6.1 ETDRS letters, representing an improvement of +5.0 ETDRS letters compared to sham-treated subjects. Related: UNITY Biotech Stock
The study, which was recently published in the journal “Scientific Reports,” found that gait patterns among Japanese children aged 6 to 12 vary from those in other developed countries. Age related variations in lower limb movements while walking were studied by scientists from Nagoya University in Japan. For Japanese children in the 11-12 year age group, the number of steps performed each minute was higher than those in the 6-8 year age group.
New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
As back-to-school approaches the CDC no longer recommends quarantining if exposed to the omicron virus.
In the recall expansion, “botulism” has been mentioned.
Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.
The pharma giant hit back at allegations that the use of Zantac, known chemically as ranitidine, increases the risk of cancer.
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Friends up north and across Tampa Bay snickered when Brian Lafferty revealed where he’d bought a new home. His 30-year-old daughter in Boston called to express concern. Even his ex-wife asked him about it. “Without exception, every person I’ve told I bought a house in The Villages has asked the same thing,” Lafferty said. “‘Isn’t that the STD capital of the United States?’” The Villages, a ...
The Supreme Court decision to overturn Roe v Wade triggered a wave of outrage from pro-choice groups as states moved quickly to criminalize abortion. Now, investors are taking action with their dollars, deploying capital to support women’s health startups.
Joining me on the call today are Sujal Shah, chief executive officer; Chuck McWherter, chief scientific officer; Dennis Kim, chief medical officer; Lewis Stuart, chief commercial officer; and Dan Menold, VP, finance. Following our prepared remarks, we will open the call for Q&A. Before we begin, I'd like to remind everyone that statements made during this conference call, including the Q&A session relating to CymaBay's expected future performance, business prospects, events or plans, including clinical plans, regulatory approvals, funding and repayment schedules, anticipated time lines and data release date, cash runway and planning for commercialization are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.
Everything you need to know about the biggest changes to U.S. health policy since the Affordable Care Act
The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.
As Americans shake off pandemic trends and return to the gym, fitness chains like Planet Fitness (PLNT) are seeing increased membership sign-ups — particularly from one demographic.
The House moved Friday to pass a sweeping climate and health care bill, delivering a long-awaited legislative win to President Biden’s desk for his signature. The White House is preparing to deploy officials across the country to promote the historic action on climate change and lowering prescription drug costs contained in the bill, pitching it…
The FDA has repeatedly cited India's Aurobindo for unsafe manufacturing practices, but still lets it dominate the U.S. market for generic drugs.
The new rules go into effect later this month.
Joining me on today's call are RA Session II Taysha's president, founder, and CEO; Dr. Frederick Porter, chief technical officer; Dr. Suyash Prasad, chief medical officer and head of R&D and Kamran Alam, chief financial officer. After our formal remarks, we will conduct a question-and-answer session and instructions will follow at that time.